Coming Soon
Find information on Choroidal Melanoma (C), also known as Uveal Melanoma or Intraocular Melanoma, for accurate clinical documentation and medical coding. This resource provides details relevant to healthcare professionals regarding diagnosis, treatment, and management of Choroidal Melanoma, supporting comprehensive patient care and accurate medical records. Learn about Intraocular Melanoma ICD codes, Uveal Melanoma staging, and Choroidal Melanoma treatment options. Improve your understanding of this rare eye cancer for optimized healthcare workflows.
Also known as
Malignant neoplasm of choroid
Cancer originating in the choroid layer of the eye.
Malignant neoplasm of eye and adnexa
Cancers affecting various parts of the eye and surrounding tissues.
Malignant neoplasms
A broad category encompassing various types of cancers.
Follow this step-by-step guide to choose the correct ICD-10 code.
Is the melanoma of the choroid confirmed?
When to use each related code
| Description |
|---|
| Cancer arising from the choroid of the eye. |
| Cancer involving iris, ciliary body, or choroid. |
| Melanoma located within the eye. |
Missing or incorrect laterality (right, left, bilateral) for choroidal melanoma impacts reimbursement and data accuracy.
Inadequate documentation of tumor size and location within the choroid can lead to coding errors and affect staging.
Lack of histological confirmation for the diagnosis of choroidal melanoma can create audit risks and coding discrepancies.
Q: What are the most effective current treatment strategies for managing medium-sized choroidal melanoma in a patient with good visual acuity?
A: Managing medium-sized choroidal melanoma with good visual acuity requires a personalized approach balancing tumor control and vision preservation. Current evidence-based treatment options include plaque brachytherapy, proton beam therapy, and stereotactic radiosurgery. Brachytherapy offers localized radiation delivery, while proton therapy and radiosurgery minimize radiation to surrounding healthy tissues. The choice depends on factors like tumor size, location, patient preferences, and access to specialized centers. Selecting the appropriate treatment necessitates a multidisciplinary team discussion involving ophthalmologists, oncologists, radiation therapists, and potentially medical physicists. Explore how different treatment modalities impact visual outcomes and quality of life to inform shared decision-making with the patient. Consider implementing a comprehensive follow-up protocol with regular ophthalmic examinations and imaging to monitor tumor response and manage potential complications such as radiation retinopathy or optic neuropathy.
Q: How do I differentiate choroidal melanoma from choroidal nevus on fundus examination and multimodal imaging, and when is biopsy indicated for diagnostic confirmation?
A: Differentiating choroidal melanoma from a benign choroidal nevus is crucial for appropriate management. Key features on fundus examination suggestive of melanoma include thickness greater than 2mm, subretinal fluid, orange pigment (lipofuscin), and documented growth. Multimodal imaging such as ultrasound biomicroscopy (UBM), fundus autofluorescence (FAF), and optical coherence tomography (OCT) can provide further information on tumor characteristics and help assess risk. UBM can help determine tumor thickness and internal reflectivity. FAF can identify lipofuscin accumulation, and OCT can detect subretinal fluid and other related retinal changes. While these imaging modalities aid in risk stratification, biopsy is rarely indicated for diagnosis due to the potential risks of complications such as tumor seeding. Instead, close monitoring with serial imaging is generally preferred for suspicious nevi. However, in cases with high suspicion of melanoma despite inconclusive imaging, or in cases with atypical features, fine-needle aspiration biopsy (FNAB) may be considered after careful evaluation of the risks and benefits. Learn more about the specific characteristics of each imaging modality and their role in the diagnostic pathway for choroidal lesions.
Patient presents with concerning symptoms suggestive of choroidal melanoma, including blurred vision, visual field defects, flashes of light (photopsia), and metamorphopsia. Differential diagnosis includes choroidal nevus, retinal detachment, and other intraocular tumors. Ophthalmoscopic examination reveals a pigmented lesion consistent with uveal melanoma, located in the choroid of the right eye. Ultrasound biomicroscopy (UBM) and optical coherence tomography (OCT) were performed to assess tumor dimensions, basal diameter, thickness, and internal reflectivity. Findings confirmed a suspicious choroidal mass with characteristics concerning for malignancy. Fluorescein angiography and indocyanine green angiography were conducted to evaluate the vascularity of the lesion and potential retinal involvement. Given the clinical presentation and imaging findings, a presumptive diagnosis of intraocular melanoma is made. Management options including brachytherapy, enucleation, and other treatment modalities were discussed with the patient. Referral to an ocular oncologist is scheduled for further evaluation, confirmation of diagnosis via biopsy if deemed necessary, and definitive treatment planning. Patient education regarding choroidal melanoma prognosis, potential complications, and follow-up care was provided. ICD-10 code C69.3 (malignant neoplasm of choroid) is documented. CPT codes for the diagnostic procedures performed are also recorded for medical billing and coding purposes. The patient will be closely monitored for treatment response and disease progression.